Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Healthcare organisations can be more resilient, agile and innovative: EY report
The report, released at BioAsia 2022, highlighted how healthcare organisations need to create the right data environment to…
Mandaviya releases reports highlighting India’s COVID vaccination programme
The reports titled 'COVID-19 - India's Vaccine Development Story' and 'India's COVID-19 Vaccination Administration Journey'…
COVID vaccine supply for global programme outstrips demand for first time
As supply and donations have ramped up, poorer nations are facing hurdles such as gaps in cold-chain shortage, vaccine hesitancy…
We are making a ‘pancorona virus’ vaccine that will protect against all coronavirus variants: Dr…
During BioAsia 2022, Genome Valley Excellence Award recipient, Dr Weissman talked about mutations, mRNA technology, new vaccines…
GSK to name consumer healthcare unit ‘Haleon’ after spin-off
Last June, GSK announced plans to divest the business, which includes brands such as Sensodyne toothpaste and Advil painkillers,…
European medicines regulatory network adopts EU common standard for electronic product information
The Product Information (PI) of a medicine includes the package leaflet for patients and the summary of product characteristics…
COVID vaccine doesn’t raise risk of rare inflammation in children: Lancet
The reporting rate of MIS-C for those without evidence of SARS-CoV-2 infection was 0.3 cases per million vaccinated individuals
Eli Lilly announces Institute for Genetic Medicine and $700 million investment in Boston Seaport…
The facility will headquarter research efforts in Boston and New York to accelerate the development of RNA and DNA-based medicines
WHO establishes global biomanufacturing training hub in Republic of Korea
Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub
Sanofi and GSK to seek regulatory authorisation for COVID-19 vaccine
Final analysis of the global VAT02 booster trial confirms universal ability to boost neutralising antibodies 18-to 30-fold across…